HIV-1 non-B subtypes: High transmitted NNRTI-resistance in Spain and impaired genotypic resistance interpretation due to variability

Antiviral Research

Volumn 85, Issue 2, 2010, Pages 409-417

  Yebra, G ^a   de Mulder, M ^a   del Romero, J ^b   Rodriguez C ^b   Holguin A ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b CENTRO SANITARIO SANDOVAL   (Spain)

Author keywords

Drug resistance mutations; Genotypic resistance algorithms; HIV 1 subtypes; Subtyping tools

Indexed keywords

ABACAVIR; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; POL PROTEIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENETIC ALGORITHM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATIONAL ANALYSIS; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; RELIABILITY; SPAIN; VIRUS CLASSIFICATION; VIRUS GENOME; VIRUS RECOMBINANT;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PHYLOGENY; POLYMORPHISM, GENETIC; PREVALENCE; SEQUENCE ANALYSIS, DNA; SPAIN;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 74449091177     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.11.010     Document Type: Article

References (41)

1. Aggarwal I., Smith M., Tatt I.D., Murad S., Osner N., Geretti A.M., and Easterbrook P.J. Evidence for onward transmission of HIV-1 non-B subtype strains in the United Kingdom. J. Acquir. Inmune Defic. Syndr. 41 (2006) 201-209
2. Agwale S.M., Zeh C., Paxinos E., Odama L., Pienazek D., Wambebe C., Kalish M.L., and Ziermann R. Genotypic and phenotypic analyses of human immunodeficiency virus type 1 in antiretroviral drug-naive Nigerian patients. AIDS Res. Hum. Retroviruses 22 (2006) 22-26
3. Bennett D.E., Camacho R.J., Otelea D., Kuritzkes D.R., Fleury H., Kiuchi M., Heneine W., Kantor R., Jordan M.R., Schapiro J.M., Vandamme A.M., Sandstrom P., Boucher C.A., van de Vijver D., Rhee S.Y., Liu T.F., Pillay D., and Shafer R.W. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 4 (2009) e4724
4. Booth C.L., and Geretti A.M. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J. Antimicrob. Chemother. 59 (2007) 1047-1056
5. Champenois K., Bocket L., Deuffic-Burban S., Cotte L., André P., Choisy P., and Yazdanpanah Y. Expected response to protease inhibitors of HIV-1 non-B subtype viruses according to resistance algorithms. AIDS 22 (2008) 1087-1089
6. de Mendoza C., Rodríguez C., Colomina J., Tuset C., García F., Eirós J.M., Corral A., Leiva P., Agüero J., Torre-Cisneros J., Pedreira J., Viciana I., del Romero J., Sáez A., Ortiz de Lejarazu R., and Soriano V. Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. Clin. Infect. Dis. 41 (2005) 1350-1354
7. Delgado E., Thomson M.M., Villahermosa M.L., Sierra M., Ocampo A., Miralles C., Rodríguez-Pérez R., Diz-Aren J., Ojea-de Castro R., Losada E., Cuevas M.T., Vázquez-de Parga E., Carmona R., Pérez-Alvarez L., Medrano L., Cuevas L., Tabeada J.A., and Nájera R. Identification of a newly characterized HIV-1 BG intersubtype circulating recombinant form in Galicia, Spain, which exhibits a pseudotype-like virion structure. J. Acquir. Immune Defic. Syndr. 29 (2002) 536-543
8. Geretti A.M. Epidemiology of antiretroviral drug resistance in drug-naïve persons. Curr. Opin. Infect. Dis. 20 (2007) 22-32
9. Gutiérrez M., Tajada P., Álvarez A., De Julián R., Baquero M., Soriano V., and Holguín A. Prevalence of HIV-1 non-B subtypes, syphilis, HTLV and Hepatitis B and C viruses among immigrant sex workers in Madrid, Spain. J. Med. Vir. 74 (2004) 521-527
10. Hemelaar J., Gouws E., Ghys P.D., and Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20 (2006) w13-23
11. Holguín A., Álvarez A., and Soriano V. Heterogeneous nature of HIV-1 recombinants spreading in Spain. J. Med. Virol. 75 (2005) 374-380
12. Holguín A., Suñe C., Hamy F., Soriano V., and Klimkait T. Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. J. Clin. Virol. 36 (2006) 264-271
13. Holguín A., Ramírez de Arellano E., Rivas P., and Soriano V. Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes. AIDS Rev. 8 (2006) 98-107
14. Holguín A., Pena M.J., Troncoso F., and Soriano V. Introduction of non-B subtypes among Spaniards newly diagnosed with HIV type 1 in the Canary Islands. AIDS Res. Hum. Retroviruses 23 (2007) 498-502
15. Holguín A., de Mulder M., Yebra G., López M., and Soriano V. Increase of non-B subtypes and recombinants among newly diagnosed HIV-1 native Spaniards and immigrants in Spain. Curr. HIV Res. 6 (2008) 327-334
16. Holguín A., López M., and Soriano V. Reliability of rapid subtyping tools compared to that of phylogenetic analysis for characterization of human immunodeficiency virus type 1 non-B subtypes and recombinant forms. J. Clin. Microbiol. 46 (2008) 3896-3899
17. Johnson V.A., Brun-Vezinet F., Clotet B., Gunthard H.F., Kuritzkes D.R., Pillay D., Schapiro J.M., and Richman D.D. Update of the drug resistance mutations in HIV-1: spring 2008. Top. HIV Med. 16 (2008) 62-68
18. Kantor R., and Katzenstein D. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev. 5 (2003) 25-35
19. Kijak G.H., Rubio A.E., Pampero S.E., Zala C., Cahn P., Galli R., Montaner J.S., and Salomón H. Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms. HIV Med. 4 (2003) 72-78
20. Martínez-Cajas J.L., Pant-Pai N., Klein M.B., and Wainberg M.A. Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev. 10 (2008) 212-223
21. Martínez-Picado J., Gutiérrez C., de Mendoza C., Erkicia I., Domingo P., Camino X., Galindo M.J., Blanco J.L., Leal M., Masabeu A., Guelar A., Llibre J.M., Margall N., Iribarren J., Gutiérrez S., Baldoví J.F., Pedreira J.D., Gatell J.M., Moreno S., Clotet B., Soriano V., and Ruiz L. Surveillance of drug resistance and HIV subtypes in newly diagnosed patients in Spain during 2004 [abstract 124]. 14th International HIV Drug Resistance Workshop. Quebec, Canada (2005)
22. Muñoz M., Carmona R., Pérez-Álvarez L., Cilla G., Suárez M.D., Delgado E., Contreras G., Corral J., de Goicoetxea M.J., Medrano L., Lezaún M.J., and Nájera R. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain. J. Clin. Virol. 33 (2005) 224-229
23. Ntemgwa M., Gill M.J., Brenner B.G., Moisi D., and Wainberg M.A. Discrepancies in assignment of subtype/recombinant forms by genotyping programs for HIV type 1 drug resistance testing may falsely predict superinfection. AIDS Res. Hum. Retroviruses 24 (2008) 995-1002
24. Nyombi B.M., Holm-Hansen C., Kristiansen K.I., Bjune G., and Müller F. Prevalence of reverse transcriptase and protease mutations associated with antiretroviral drug resistance among drug-naïve HIV-1 infected pregnant women in Kagera and Kilimanjaro regions, Tanzania. AIDS Res. Ther. 5 (2008) 13
25. Ojesina A.I., Sankalé J.L., Odaibo G., Langevin S., Meloni S.T., Sarr A.D., Olaleye D., and Kanki P.J. Subtype-specific patterns in HIV Type 1 reverse transcriptase and protease in Oyo State, Nigeria: implications for drug resistance and host response. AIDS Res. Hum. Retroviruses 22 (2006) 770-779
26. Palacios R., Viciana I., Pérez de Pedro I., de la Torre J., Ropero F., Fernández S., Salgado F., Roldán J., de Dios Colmenero J., Márquez M., Santos J., and Grupo Malagueño para el Estudio de las Enfermedades Infecciosas. Prevalence of primary resistance mutations in patients with newly diagnosed HIV infection in the province of Málaga (Spain). Enferm. Infect. Microbiol. Clin. 26 (2008) 141-145
27. Pillonel J., Barin F., Laperche S., Bernillon P., Le Vu S., Brunet S., Thierry D., Desenclos J.C., and Transfusion-Transmissible Agents Working Group of the French Society of Blood Transfusion. Human immunodeficiency virus type 1 incidence among blood donors in France, 1992 through 2006: use of an immunoassay to identify recent infections. Transfusion 48 (2008) 1567-1575
28. Poonpiriya V., Sungkanuparph S., Leechanachai P., Pasomsub E., Watitpun C., Chunhakan S., and Chantratita W. A study of seven rule-based algorithms for the interpretation of HIV-1 genotypic resistance data in Thailand. J. Virol. Methods 151 (2008) 79-86
29. Ravela J., Betts B.J., Brun-Vézinet F., Vandamme A.M., Descamps D., van Laethem K., Smith K., Schapiro J.M., Winslow D.L., Reid C., and Shafer R.W. HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J. Acquir. Immune Defic. Syndr. 33 (2003) 8-14
30. Rhee S.Y., Fessel W.J., Liu T.F., Marlowe N.M., Rowland C.M., Rode R.A., Vandamme A.M., Van Laethem K., Brun-Vezinet F., Calvez V., Taylor J., Hurley L., Horberg M., and Shafer R.W. Predictive value of HIV-1 genotypic resistance test interpretation algorithms. J. Infect. Dis. 200 (2009) 453-463
31. Sagir A., Oette M., Kaiser R., Däumer M., Fätkenheuer G., Rockstroh J.K., Knechten H., Schmutz G., Hower M., Emmelkamp J., Pfister H., Häussinger D., and RESINA Study Team. Trends of prevalence of primary HIV drug resistance in Germany. J. Antimicrob. Chemother. 60 (2007) 843-848
32. Sanchez-Oñoro M., López M.J., Santana M.A., Andés J.M., and Campelo F.A. Primary antiretroviral drug resistance among patients diagnosed with HIV infection in Gran Canaria (Spain) between 2002 and 2005. Enferm. Infect. Microbiol. Clin. 25 (2007) 437-440
33. Shet A., Berry L., Mohri H., Mehandru S., Chung C., Kim A., Jean-Pierre P., Hogan C., Simon V., Boden D., and Markowitz M. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J. Acquir. Immune Defic. Syndr. 41 (2006) 439-446
34. Smith D., Moini M., Pesano R., Cachay E., Aiem H., Lie Y., Richman D., and Little S. Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection. Clin. Infect. Dis. 44 (2007) 456-458
35. Snoeck J., Kantor R., Shafer R.W., Van Laethem K., Deforche K., Carvalho A.P., Wynhoven B., Soares M.A., Cane P., Clarke J., Pillay C., Sirivichayakul S., Ariyoshi K., Holguín A., Rudich H., Rodrigues R., Bouzas M.B., Brun-Vézinet F., Reid C., Cahn P., Brigido L.F., Grossman Z., Soriano V., Sugiura W., Phanuphak P., Morris L., Weber J., Pillay D., Tanuri A., Harrigan R.P., Camacho R., Schapiro J.M., Katzenstein D., and Vandamme A.M. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob. Agents Chemother. 50 (2006) 694-701
36. SPREAD programme. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 22 (2008) 625-635
37. UNAIDS Joint United Nations Programme on HIV/AIDS, 2009. 2008 Report on the global AIDS epidemic, second electronic edition. Available at: http://data.unaids.org/pub/GlobalReport/2008/JC1511_GR08_ExecutiveSummary_en.pdf (23 June 2009, date last accessed).
38. Vergne L., Snoeck J., Aghokeng A., Maes B., Valea D., Delaporte E., Vandamme A.M., Peeters M., and Van Laethem K. Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naïve and treated patients. FEMS Immunol. Med. Microbiol. 46 (2006) 53-62
39. Vessière A., Nerrienet E., Kfuţwah A., Menu E., Tejiokem M., Pinson-Recordon P., Barré-Sinoussi F., Fleury H., and Ayouba A. HIV-1 pol gene polymorphism and antiretroviral resistance mutations in drug-naive pregnant women in Yaoundé, Cameroon. J. Acquir. Immune Defic. Syndr. 42 (2006) 256-258
40. Wensing A.M., van de Vijver D.A., Angarano G., Asjö B., Balotta C., Boeri E., Camacho R., Chaix M.L., Costagliola D., De Luca A., Derdelinckx I., Grossman Z., Hamouda O., Hatzakis A., Hemmer R., Hoepelman A., Horban A., Korn K., Kücherer C., Leitner T., Loveday C., MacRae E., Maljkovic I., de Mendoza C., Meyer L., Nielsen C., Op de Coul E.L., Ormaasen V., Paraskevis D., Perrin L., Puchhammer-Stöckl E., Ruiz L., Salminen M., Schmit J.C., Schneider F., Schuurman R., Soriano V., Stanczak G., Stanojevic M., Vandamme A.M., Van Laethem K., Violin M., Wilbe K., Yerly S., Zazzi M., Boucher C.A., and SPREAD Programme. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J. Infect. Dis. 192 (2005) 958-966
41. Wheeler W., Mahle K., Bodnar U.R., Kline R., Hall H.I., and McKenna M.T. Antiretroviral drug-resistance mutations and subtypes in drug-naïve persons newly diagnosed with HIV-1 infection, US, March 2003 to October 2006 [Abstract 648]. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, USA (2007)